Botanix Pharmaceuticals Investor Relations Material

Botanix Pharmaceuticals Limited is a clinical-stage pharmaceutical company focused on developing treatments for dermatological and antimicrobial conditions. The company's pipeline leverages synthetic cannabidiol (CBD) to address skin diseases such as acne, rosacea, and atopic dermatitis, as well as infections caused by antimicrobial-resistant bacteria. Botanix’s products aim to offer innovative therapies that address unmet medical needs, especially in dermatology, by combining novel formulations with delivery systems that enhance drug efficacy. The company is headquartered in North Perth, Australia, and its shares are listed on the ASX.